HC Wainwright Weighs in on Immunocore Holdings plc’s Q1 2023 Earnings (NASDAQ:IMCR)

Immunocore Holdings plc (NASDAQ:IMCR – Get Rating) – Equities researchers at HC Wainwright decreased their Q1 2023 earnings per share estimates for Immunocore in a report released on Wednesday, March 8th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn $0.02 per share for the quarter, down from their prior forecast of $0.13. HC Wainwright has a “Buy” rating and a $90.00 price objective on the stock. The consensus estimate for Immunocore’s current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for Immunocore’s Q2 2023 earnings at $0.02 EPS, Q3 2023 earnings at $0.02 EPS, Q4 2023 earnings at $0.02 EPS, FY2023 earnings at $0.11 EPS, FY2024 earnings at $0.47 EPS, FY2025 earnings at $0.18 EPS, FY2026 earnings at $1.36 EPS and FY2027 earnings at $2.85 EPS.

IMCR has been the subject of a number of other research reports. The Goldman Sachs Group raised Immunocore from a “neutral” rating to a “buy” rating and upped their target price for the stock from $33.00 to $80.00 in a research report on Friday, December 16th. Barclays began coverage on Immunocore in a research report on Wednesday, November 30th. They set an “overweight” rating and a $80.00 target price for the company. Finally, Oppenheimer upped their target price on Immunocore from $65.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 15th. Ten equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $78.33.

Immunocore Stock Down 3.0 %

Shares of Immunocore stock opened at $51.39 on Monday. The stock has a market capitalization of $2.26 billion, a P/E ratio of -45.08 and a beta of 0.61. The company has a quick ratio of 4.71, a current ratio of 4.72 and a debt-to-equity ratio of 0.24. The stock has a 50 day moving average price of $58.48 and a two-hundred day moving average price of $55.44. Immunocore has a 12-month low of $23.99 and a 12-month high of $69.06.

Institutional Investors Weigh In On Immunocore

Hedge funds have recently modified their holdings of the business. Assetmark Inc. boosted its position in shares of Immunocore by 95.5% in the fourth quarter. Assetmark Inc. now owns 608 shares of the company’s stock valued at $35,000 after acquiring an additional 297 shares during the period. Wells Fargo & Company MN raised its stake in shares of Immunocore by 89.7% in the fourth quarter. Wells Fargo & Company MN now owns 827 shares of the company’s stock valued at $47,000 after purchasing an additional 391 shares in the last quarter. Royal Bank of Canada acquired a new position in shares of Immunocore in the first quarter valued at $79,000. Tower Research Capital LLC TRC raised its stake in shares of Immunocore by 1,003.5% in the third quarter. Tower Research Capital LLC TRC now owns 3,145 shares of the company’s stock valued at $148,000 after purchasing an additional 2,860 shares in the last quarter. Finally, JTC Employer Solutions Trustee Ltd acquired a new position in shares of Immunocore in the fourth quarter valued at $223,000. 65.11% of the stock is owned by institutional investors.

Immunocore Company Profile

(Get Rating)

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers.